Alzheimer's vaccine takes first step in human trial
NCT ID NCT06831812
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a vaccine called AV-1959R, designed to prevent Alzheimer's disease by targeting a protein linked to the condition. Sixteen healthy adults aged 40-60 will receive three shots of the vaccine or a placebo over 14 weeks. Researchers will monitor for side effects and measure immune responses to see if the vaccine is safe and triggers the desired effect.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AV-1959R (beta-amyloid vaccine)
- What this could lead to
- If successful, this could lead to a vaccine that prevents Alzheimer's disease by training the immune system to clear harmful brain proteins.
- What could go wrong
- This is an early Phase 1 trial with only 16 healthy participants, so safety and immune response are unproven. The vaccine may not work in larger studies or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
16 people
The number who actually took part.
- Started
-
Jun 2024
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy male or female adults, 40-60 years old. * BMI 18.0-32.0 kg/m². * No significant medical conditions or abnormal MRI, ECG, or lab tests. * Signed informed consent and ability to follow study procedures. * Females must be postmenopausal or surgically sterile. * Males must use contraception or be vasectomized. Exclusion Criteria: * History of Alzheimer's, stroke, or neurodegenerative disease. * MRI abnormalities, such as infarcts or microbleeds. * Serious illness, surgery, or hospitalization in the last 4 weeks. * Significant heart, lung, liver, kidney, or immune disorders. * Recent drug/alcohol abuse or severe allergies. * Abnormal lab tests (e.g., high liver enzymes, kidney dysfunction, HIV, Hepatitis B/C positive). * Use of investigational drugs or amyloid/tau therapies in the last year. * Chronic use of immunosuppressants, anticoagulants, or blood products. * Pregnant, breastfeeding, or women of childbearing potential. * Recent blood donation (\>400 mL) in the last 30 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arvax
Adelaide, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glutathione, brain metabolism and inflammation in Alzheimer's disease
- Can an experimental infusion reach the brain to fight Alzheimer's?
- A new roadmap to predict Alzheimer's before memory fails
- Can a 500-Person study unlock Alzheimer's early signs?
- AI hunts for early clues to Parkinson's and Alzheimer's progression
- Gut bacteria may hold clues to memory decline